Immune Response, In-Vitro and Vaccination - Clinical Research Informer

Ixchiq Wins FDA Approval as World’s First Chikungunya Vaccine

XTalks

NOVEMBER 15, 2023

France-based biotech Valneva has won approval from the US Food and Drug Administration (FDA) for its chikungunya vaccine Ixchiq for the prevention of infection from the chikungunya virus. The vaccine is approved for adults 18 years of age and older who are at increased risk of exposure to the virus.

FDA Approval

FDA Approval Vaccination Vaccine In-Vitro

Budget 2021: Sunak focuses on vaccine development to restart economy

pharmaphorum

MARCH 4, 2021

UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. A scheme providing £500 payments to people self-isolating has been extended in England until the summer.

Vaccination

Vaccination Vaccine Development Life Science

CohBar and Morphogenesis in merger for immuno-oncology therapies

Pharmaceutical Technology

MAY 24, 2023

Morphogenesis’s technologies include Immune Fx (IFx) personalised cancer vaccines and tumour microenvironment (TME) modulators. IFx has been designed to activate an innate immune response against tumour antigens that are patient-specific. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

Gene Therapy

Gene Therapy In-Vivo In-Vitro Immune Response

COVID-19 Vaccine Messaging: Why Vaccine Efficacies Can’t Be Compared and Shopped

XTalks

MARCH 2, 2021

As the US Food and Drug Administration (FDA) handed out an emergency use authorization (EUA) to Janssen’s COVID-19 vaccine over the weekend — making it the third authorized COVID-19 vaccine in the US — many people became laser-focused on the 66 percent average efficacy of the single-dose shot.

Vaccination

Vaccination Vaccine Trials Clinical Trials

A protein-based COVID-19 vaccine that mimics the shape of the virus

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein

Protein Vaccination Vaccine Antibody

Pfizer/BioNTech COVID-19 Vaccine Trial Results: Stellar, Long-Ranging Efficacies in Children and Against Variants

XTalks

APRIL 2, 2021

Pfizer released new COVID-19 vaccine trial results this week from its ongoing clinical studies, which include data showing that its COVID-19 mRNA vaccine is 100 percent effective in children between the ages of 12 and 15 and has a 91 percent efficacy against variants with protection lasting at least six months.

Vaccination

Vaccination Vaccine Trials Clinical Trials

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. 1 Specifically, the test targets antibodies which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell.

Antibody

Antibody Vaccination Vaccine In-Vitro

Taking an ‘upside-down’ approach to mRNA delivery

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution.

Vaccination

Vaccination Vaccine In-Vivo In-Vitro

How T Cell Tests Could Trump Antibody Tests in the Detection of COVID-19

XTalks

NOVEMBER 20, 2020

The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2. Traditional antibody tests for uncovering past infections involve detection of antigen-specific antibodies produced during an immune response against a pathogen.

Antibody

Antibody Immune Response Protein In-Vitro

2021 Biopharma Update on the Novel Coronavirus: January 12

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . One of the open questions about the various vaccines against COVID-19 has been how long the protection offered will last. Diagnostics.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

The Pharma Data

JUNE 17, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). However, immunocompromised individuals still lack effective immunity against SARS-CoV-2 infection.

Antibody

Antibody In-Vivo In-Vitro Immune Response

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

MARCH 25, 2022

People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld. People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld. 2-4 Evusheld was generally well-tolerated in the trial.(2-4).

Antibody

Antibody In-Vivo Medicine Vaccination

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

Evusheld has the potential to provide long-lasting protection against COVID-19 for a broad population of individuals, including those who aren’t adequately protected by a COVID-19 vaccine, as well as those at increased risk of exposure.”. 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial.

Antibody

Antibody In-Vivo Vaccination Vaccine

Chemical found in leafy greens shown to slow growth of COVID-19 and common cold viruses

The Pharma Data

MARCH 23, 2022

Researchers at Johns Hopkins Children’s Center report evidence from lab experiments that a chemical derived from a compound found abundantly in broccoli and other cruciferous plants may offer a potentially new and potent weapon against the viruses that cause COVID-19 and the common cold. alone each year. µM) and remdesivir (for example, 0.5-3.2

Immune Response

Immune Response In-Vitro Research Scientist

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination

Vaccination Vaccine Antibody Life Science

Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations

The Pharma Data

MARCH 16, 2021

Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1 Viruses naturally evolve over time.

Antibody

Antibody Clinical Trials Clinical Trials Vaccination

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Manufacturing

Manufacturing Vaccination Vaccine RNA

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

The Pharma Data

JANUARY 11, 2021

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.

Antibody

Antibody Licensing Licensing Development

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

JULY 22, 2022

Immunotherapies have become more popular due to their ability to trigger and train the patient’s immune system to recognise and attack tumour cells, provide strong immune responses, and reduce the severity of adverse side effects generally associated with chemotherapies. Jespersen et al.

In-Vivo

In-Vivo Engineer In-Vitro Antibody

PFIZER-BIONTECH COVID-19 VACCINE AND PROFOUND PUBLIC HEALTH IMPACT OF VACCINATION ONE YEAR AFTER PANDEMIC DECLARED

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research

Research In-Vitro In-Vivo Development

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Luncheon presentations will be given by Andrew Bradbury, MB BS, PhD, Chief Scientific Officer, Specifica, and Stefanie Kall, Ph.D.,

Antibody

Antibody Engineer Protein Scientist

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

AUGUST 22, 2021

AZD7442 is the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial. More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination.

Trials

Trials Antibody Vaccination Vaccine

Clinical Catch-Up: January 11-15 | BioSpace

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated.

Immune Response

Immune Response Antibody Trials Clinical Trials

Clinical Research Informer

Ixchiq Wins FDA Approval as World’s First Chikungunya Vaccine

Budget 2021: Sunak focuses on vaccine development to restart economy

Trending Sources

CohBar and Morphogenesis in merger for immuno-oncology therapies

COVID-19 Vaccine Messaging: Why Vaccine Efficacies Can’t Be Compared and Shopped

A protein-based COVID-19 vaccine that mimics the shape of the virus

Pfizer/BioNTech COVID-19 Vaccine Trial Results: Stellar, Long-Ranging Efficacies in Children and Against Variants

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines

Taking an ‘upside-down’ approach to mRNA delivery

How T Cell Tests Could Trump Antibody Tests in the Detection of COVID-19

2021 Biopharma Update on the Novel Coronavirus: January 12

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

Chemical found in leafy greens shown to slow growth of COVID-19 and common cold viruses

COVID-19 Pandemic Coverage

Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

How mice with humanised immune systems are advancing cell-based immunotherapy

PFIZER-BIONTECH COVID-19 VACCINE AND PROFOUND PUBLIC HEALTH IMPACT OF VACCINATION ONE YEAR AFTER PANDEMIC DECLARED

The evolution of assays for immuno-oncology research

What to expect from PEGS Europe 2023: Day 1

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

Clinical Catch-Up: January 11-15 | BioSpace

Stay Connected